Clinical trials: Sepsis Syndromes
Severe Sepsis
S.A.F.E.BT System Extracorporeal Treatment With DIAPACT CRRT
The purpose of this study is to determine if Selective Adsorption System for Removal of Bacterial Toxins (S.A.F.E.BT) therapy is effective in the treatment of severe sepsis.
- Trial name
- SAFEbt (NCT01312675)
- Testing
- S.A.F.E.BT
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- B. Braun Medical Inc.
Sepsis, Septic Shock
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving…
- Trial name
- NCT00279214
- Testing
- drotrecogin alfa (activated)
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Eli Lilly and Company
Drug Safety
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
The novel humanized monoclonal antibody CaCP29 was developed to control the inflammatory response to various stimuli in humans and espacially during sepsis.
- Trial name
- NCT01319903
- Testing
- CaCP29, a humanized monoclonal antibody
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- InflaRx GmbH
Sepsis, Severe Sepsis
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
The purpose of this study is to determine if levels of ischemia modified albumin (IMA) in blood are elevated in patients with suspected infection and are predictive of severity of illness in patients with sepsis.
- Conditions
- Sepsis, Severe Sepsis, Systemic Inflammatory Response Syndrome, Sepsis Syndrome
- Trial name
- NCT00448968
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Inverness Medical Innovations
Sepsis, Adult Disease
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in…
- Conditions
- Sepsis, Adult Disease, Severe Sepsis, Emergency Department
- Trial name
- NCT04353388
- Testing
- CBC-DIFF Monocyte Volume Width Distribution (MDW)
- Where
- United States
- Volunteers
- 1,139 people
- Sponsor
- Beckman Coulter, Inc.
Sepsis, Severe Sepsis
Machine Learning Sepsis Alert Notification Using Clinical Data
Machine learning is a powerful method to create clinical decision support (CDS) tools, when training labels reflect the desired alert behavior.
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- HindSight P2 (NCT04005001)
- Testing
- HindSight, InSight
- Where
- 3 sites in United States
- Volunteers
- 37,986 people, healthy volunteers welcome
- Sponsor
- Dascena
Candidiasis, Candidemia
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
- Trial name
- NCT00105144
- Testing
- Micafungin, Caspofungin
- Where
- 167 sites in United States, Austria and 13 more
- Volunteers
- 611 people
- Sponsor
- Astellas Pharma Inc
Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
The purpose of this study is to further evaluate the safety and effectiveness of intravenous anidulafungin (Eraxis™) in patients with a diagnosis of candidemia or invasive candidiasis, which is a fungus infection of the blood or…
- Trial name
- NCT00496197
- Testing
- Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
- Where
- 43 sites in United States, South Korea
- Volunteers
- 282 people
- Sponsor
- Pfizer
Systemic Inflammatory Response Syndrome, Acute Kidney Injury
High Cut Off Dialysis in Systemic Inflammatory Response Syndrome Patients After Cardiac Surgery
A high cut off dialyzer (septeX) is tested in patients after cardio-thoracic surgery with incidence of "systemic inflammatory response syndrome" (SIRS) and associated increased risk for acute kidney injury (AKI).
- Trial name
- HICOSIRS (NCT01579396)
- Testing
- septeX, standard therapy
- Where
- Germany
- Sponsor
- Vantive Health LLC
Biomarkers, Acute Kidney Injury
Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
The goal of this observational study is to understand whether a wearable sensor (the Nutromics Sensor Device) can accurately measure drug and biomarker levels in the fluid just under the skin (interstitial fluid), instead of…
- Conditions
- Biomarkers, Acute Kidney Injury, Sepsis
- Trial name
- VENTURE (NCT07893223)
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Nutromics
Candidemia
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - <18 years) with invasive candidiasis, including candidemia (ICC).
- Trial name
- NCT00761267
- Testing
- Anidulafungin, Fluconazole
- Where
- 45 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Sepsis, Septic Shock
ARTICE® Real Data Collection & Observational Trial, Phase 4 Study
The objectives of this registry study are to: 1. Record real-life data related to the use of the ARTICE® therapy in sepsis subjects. 2. Further evaluate ARTICE® treatment efficacy. 3.
- Conditions
- Sepsis, Septic Shock, Immunoparalysis in Septic Shock
- Trial name
- ARTistry (NCT07388628)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- Artcline GmbH
Covid19, Sepsis
Feasibility Study of Hematology Parameters in COVID-19 Disease
The purpose of this study is to evaluate the potential for MDW and other CPD parameters (measured with CBC-DIFF) to identify COVID-19 diseased adult individuals presenting to the hospital with symptoms suggestive of COVID-19 or…
- Conditions
- Covid19, Sepsis, Adults, Emergency Department
- Trial name
- NCT04816630
- Testing
- CBC-Diff Monocyte Volume Width Distribution
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Beckman Coulter, Inc.
Bacteremia, Staphylococcal Infection
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
In-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform.
- Conditions
- Bacteremia, Staphylococcal Infection, Sepsis, Infection
- Trial name
- NCT00814151
- Testing
- MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
- Where
- 3 sites in United States
- Volunteers
- 712 people
- Sponsor
- MicroPhage, Inc.
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge…
- Trial name
- EUPHRATES (NCT01046669)
- Testing
- TORAYMYXIN PMX-20R (PMX cartridge), Standard medical care for septic shock
- Where
- 40 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- Spectral Diagnostics (US) Inc.
LRTI, Sepsis
Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis
The TAILORED-Treatment consortium was established to develop new tools aimed to increase the effectiveness of antibiotic and antifungal therapy, reduce adverse events, and help limit the emergence of antimicrobial resistance in…
- Conditions
- LRTI, Sepsis, Fungal Infections, Bacteremia
- Trial name
- TailoredT (NCT02025699)
- Where
- Israel
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MeMed Diagnostics Ltd.
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
- Trial name
- TIGRIS (NCT03901807)
- Testing
- Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge
- Where
- 20 sites in United States
- Volunteers
- 157 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Sepsis Newborn, Malaria
Immune Dysfunction in Newborn Sepsis
The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.
- Conditions
- Sepsis Newborn, Malaria, Immune Responses
- Trial name
- RECIPAL (NCT03780712)
- Testing
- Non applicable
- Volunteers
- 585 people
- Sponsor
- BioMérieux
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect